Search the Newsreel

AstraZeneca shares slide 7% after reports of Bristol Myers talks

Drew Angerer/Getty Images News AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) and Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) have held preliminary discussions about a potential combination that would create one of the world's largest pharmaceutical companies, according to a report by the Financial Times. For investors, a deal would …

Bristol Myers Squibb (BMY) In Early Merger Talks With AstraZeneca

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Reports indicate AstraZeneca and Bristol-Myers Squibb are in early talks regarding a potential merger. …

AstraZeneca in talks over £300bn mega-merger with US rival – reports

AstraZeneca has held talks with US rival Bristol Myers Squibb over a merger which could create a drugs giant worth more than £300 billion, according to reports. The two pharmaceutical firms have held discussions over a potential tie-up in recent months, the Financial Times …

AstraZeneca shares slide 7% on talks to buy Bristol Myers Squibb

AstraZeneca's shares fell by 7% on news of potential talks to acquire US rival Bristol Myers Squibb, a deal that could create a pharmaceutical giant worth nearly $400 billion. The acquisition would significantly expand AstraZeneca's presence in the US and mark a strategic shift …

AstraZeneca, Bristol Myers Squibb Explore US$400 Billion Merger

The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion. Continue Reading

AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE)

Drew Angerer/Getty Images News AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) and Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) have held preliminary discussions about a potential combination that would create one of the world's largest pharmaceutical companies, according to a report by the Financial Times. For investors, a deal would …

AstraZeneca And Bristol Myers Reportedly In Talks On $400 Bln Deal

(RTTNews) - AstraZeneca Plc (AZN) and Bristol Myers Squibb (BMY) are in talks over a $400 billion deal to combine the companies, Financial Times reported. Neither company has disclosed any details of the merger, and deal closure timelines are unclear. Both AstraZeneca and Bristol …

AstraZeneca and Bristol-Myers Squibb in talks over potential merger - Report

Investing.com -- AstraZeneca PLC (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) have held talks in recent months about a deal that would combine the companies into one, according to a Financial Times report. A combined entity would carry a value of nearly $400 billion, which …

AstraZeneca plots £300bn tie-up with US rival

AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb in a deal likely to raise fresh questions over the company's ties to the UK. Britain's second-most valuable company has held talks with Bristol Myers Squibb in recent months about a …

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb are reportedly in discussions for a merger that could create a pharmaceutical giant valued at approximately $400 billion. The talks have been ongoing for several months and, if successful, would make AstraZeneca the world’s fourth-largest drugmaker by market capitalization. …

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca has reportedly held talks with Bristol Myers Squibb regarding a potential merger that could create a pharmaceutical giant valued at nearly $400 billion. The Financial Times reported on Sunday that discussions have occurred in recent months, though a deal could still be delayed …

AstraZeneca, Bristol Myers held merger talks, Financial Times reports

Drew Angerer/Getty Images News AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) and Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) have held preliminary discussions about a potential combination that would create one of the world's largest pharmaceutical companies, according to a report by the Financial Times. For investors, a deal would …

AstraZeneca and Daiichi win EU label expansion for Datroway in breast cancer

AstraZeneca announced that the European Commission has approved its antibody-drug conjugate, Datroway, developed with Daiichi Sankyo, for a second breast cancer indication in the EU. This approval means the intravenous infusion will be available in the 27 EU member states, expanding its use for …

AstraZeneca stock trades steadily as oncology and vaccines underpin Q1 2026 growth

AstraZeneca Pharma India Gets Demand Notice Over Alleged Drug Overcharging

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca's Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU …

REG - AstraZeneca PLC - Datroway approved in EU for TNBC

AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) has received approval in the EU as a monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. This approval is based on …

AstraZeneca (LSE:AZN) Stock In Focus After Sone Ve Win And Mixed Ultomiris Data

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AstraZeneca reported positive Phase III results for sonesitatug vedotin in Claudin 18.2-positive advanced gastric …

AstraZeneca’s Q2 Earnings Prove It Doesn’t Need More M&A. The CEO Said So Himself.

Does AstraZeneca (LSE:AZN) Have More Value Than The Market Prices In?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca stock has delivered a 73.3% total return over the past five years, and both the intrinsic value estimate using a Discounted Cash Flow (DCF) approach and …

AstraZeneca Number of Employees 2026 | Employee Count & Headcount Data

AstraZeneca PLC (AZN) had approximately 97,021 employees worldwide as of March 2026, representing a 13.5% growth from 2023 but a 0.7% decline year-over-year in 2026. The company is actively hiring, with 3,640 job postings in 2026, and its workforce is primarily concentrated in the …

AstraZeneca Cancer Drug Targets Up to $5 Billion in Sales

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a global pharmaceutical company focused on oncology and other major therapeutic areas, could gain a potential new cancer treatment with estimated peak sales between $3 billion and $5 billion after a late-stage study produced positive topline …

Judge Dismisses AstraZeneca’s Bid To Stop Maine Pharmacy Law

A federal court has dismissed AstraZeneca's attempt to block a Maine law that regulates drug companies' contracts with pharmacies. The US District Court for the District of Maine granted the state's motion to dismiss, upholding Chapter 103 of its insurance code. This law prohibits …

AstraZeneca's drug pipeine is splitting opinion among City analysts

AstraZeneca's drug pipeine is splitting opinion among City analysts Proactive uses images sourced from Shutterstock AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drug pipeline is splitting opinion among City brokers, with Citibank upgrading its price target to 17,800p whilst analysts at Deutsche Bank repeated a 'sell' rating …

The Zacks Analyst Blog Highlights Apple, Microsoft, Amazon, LVMH, AstraZeneca, Shell, Airbus and UBS

For Immediate Release Chicago, IL – July 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in …

AstraZeneca Stock: What We Thought of Earnings

AstraZeneca's $2.63 Earnings Beat Supports $80 Billion Revenue Target

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a global pharmaceutical company focused on medicines including cancer and rare-disease treatments, maintained its 2026 and 2030 forecasts after second-quarter core earnings exceeded market expectations, helping ease some investor concern following recent clinical-trial setbacks. Core earnings …

AstraZeneca PLC 2Q Rev $15.38B

This article provides key financial results for AstraZeneca PLC's second quarter, highlighting revenues of $15.38 billion. The exact details of the earnings, including comparisons to estimates or prior periods, would be expected in the full content.

AstraZeneca PLC (AZN) Q2 2026 Earnings Call Highlights: Strong Oncology and Rare Disease Growth ...

This article first appeared on GuruFocus. Total Revenue Growth: 6% increase in the first half of 2026. Product Revenue Growth: 6% increase in the first half of 2026. Alliance Revenue Growth: 29% increase, driven by higher profit shares from partnered medicines. Core Gross Margin: …

AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure

AstraZeneca AZN reported second-quarter 2026 core earnings of $2.63 per share, which beat the Zacks Consensus Estimate of $2.50. Earnings rose 21% year over year on a reported basis and 18% at constant exchange rate (CER). Total revenues of $15.38 billion rose 6% on …

AstraZeneca’s MONTEROSA Study Tracks Real World Outcomes for STRIDE in Liver Cancer

AstraZeneca has announced an update on its MONTEROSA study, which tracks the real-world use of its STRIDE regimen (tremelimumab and durvalumab) for liver cancer across Italian centers. The observational study aims to assess patient progression to serious liver problems, quality of life, and the …

Omeros gains as AstraZeneca's Ultomiris fails in rare blood disorder

[blood cells] cosmin4000/iStock via Getty Images * The failure of a phase 3 trial of AstraZeneca's (AZN [https://seekingalpha.com/symbol/AZN]) Ultomiris (ravulizumab) phase to treat transplant-associated thrombotic microangiopathy, a rare disorder leading to blood clots and harm to small blood vessels, has led shares of Omeros …

Top Midday Stories: Nvidia Enters Into $500 Billion Partnership With SK Group; AstraZeneca Earnings Top Estimates

The Dow Jones Industrial Average was up, while the S&P 500 and Nasdaq Composite were down in late-mo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. …

AstraZeneca drug prices evolving in response to Trump policy, executive says

AstraZeneca is adjusting its pricing strategy for new drug launches in response to former U.S. President Donald Trump's "most-favoured-nation" policy, which aims to lower drug prices for Americans. This policy links U.S. medicine prices to those in other wealthy countries, intensifying pressure on European …

Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Astrazeneca (AZN) reported $15.38 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 6.4%. EPS of $2.63 for the same period compares to $2.18 a year ago. The reported revenue represents a surprise of +0.48% over the Zacks Consensus …

Astrazeneca Q2 Earnings Call Highlights

Key Points Interested in Astrazeneca Plc? Here are five stocks we like better. Solid first-half performance: AstraZeneca reported revenue growth of 6% at constant exchange rates and 11% excluding generic-competition effects, while core EPS rose 11%. The company maintained its full-year outlook and reaffirmed …